Table 2.
Patient characteristics stratified by enhanced liver fibrosis (ELF) scores
| N = 201 | Tertile 1 (n = 67) | Tertile 2 (n = 67) | Tertile 3 (n = 67) | P‐value |
|---|---|---|---|---|
| ELF < 10.76 | ELF 10.76‐11.96 | ELF > 11.96 | ||
| Age (y) | 54.7 ± 1.3 | 59.0 ± 1.6 | 56.8 ± 1.3 | .107 |
| Sex (M, %) | 49 (73) | 50 (75) | 36 (54) | .016 |
| Etiology (n, %) | ||||
| ALD | 12 (18) | 31 (46) | 39 (58) | <.001 |
| Viral | 23 (34) | 9 (13) | 8 (12) | |
| Other | 32 (48) | 27 (40) | 20 (30) | |
| Decompensation (n, %) | 22 (33) | 41 (61) | 53 (79) | <.001 |
| Varices (n, %) | ||||
| None | 31 (46) | 16 (24) | 23 (34) | .036 |
| Small | 11 (16) | 24 (36) | 16 (24) | |
| Large | 22 (33) | 26 (39) | 26 (39) | |
| (Unknown) | 3 (5) | 1 (1.5) | 2 (3) | |
| HVPG (mm Hg) | 12 (9‐18) | 18 (14‐21) | 19 (16‐21) | <.001 |
| Child score (points) | 5 (5‐5) | 6 (5‐7) | 8 (6‐10) | <.001 |
| MELD (points) | 9 (8‐12) | 10 (9‐13) | 14 (11‐17) | <.001 |
| TE (kPa) a | 18.8 (14.1‐28.1) | 30.1 (19.4‐46.5) | 48.0 (29.5‐70.0) | <.001 |
| Creatinine (mg/dL) | 0.77 (0.63‐0.96) | 0.74 (0.59‐1.06) | 0.67 (0.56‐0.90) | .222 |
| Sodium (mmol/L) | 140 (138‐142) | 138 (136‐140) | 138 (135‐140) | .001 |
| Albumin (g/dL) | 40.7 (38.7‐42.4) | 37.1 (33.3‐40.1) | 31.3 (28.1‐35.1) | <.001 |
| INR | 1.2 (1.1‐1.4) | 1.3 (1.2‐1.4) | 1.5 (1.4‐1.7) | <.001 |
| Platelets (g/L) | 98 (65‐133) | 105 (77‐141) | 101 (76‐132) | .258 |
Abbreviations: ALD, alcohol‐related liver disease; ELF, enhanced liver fibrosis score; HVPG, hepatic venous pressure gradient; INR, international normalized ratio; M, male gender; MELD, model for end‐stage liver disease score; VCTE, vibration‐controlled transient elastography.
P‐values < .05 are indicated in bold.
a
Reliable TE results available in n = 59 (87.5%), n = 49 (88.1%) and n = 53 (79.1%) patients, respectively.